Neoadjuvant Tislelizumab + LM-302 + S-1 or Tislelizumab + SOX for CLDN18.2-Positive Gastric/GEJ Adenocarcinoma

Clinical trial NCT07569068 · RECRUITING

Trial details

NCT number: NCT07569068
Sponsor: Ruijin Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Gastric or Esophagogastric Junction Adenocarcinoma

Start date: 2026-04-21
Primary completion: 2028-04-30
Enrollment: 88

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.